Our approach to biological drugs (and to high-cost complex drugs* )
To ensure the sound management of our group benefit programs, SSQ Insurance is embarking on an initiative to promote the use of biosimilar drugs (also known as subsequent entry biologics or SEBs).
As a result, when a biosimilar version exists to replace a reference biologic product, SSQ Insurance will only reimburse the biosimilar equivalent. Our position reflects the guidelines issued by several provincial public programs in compliance with Health Canada policies.However, all participants being treated with a reference biologic product as a result of a preauthorization will be entitled to reimbursement.
What are biosimilars?
Health Canada has plenty of information available on biologic drugs and biosimilars.
For more information, consult our FAQ section.
* SSQ Insurance’s approach to high-cost complex drugs is the same as for biologics.